Powerful Intelligence for Dealmakers
Co-promotion agreement for olmesartan medoxomil
| Companies: |
Pfizer Daiichi Sankyo |
|---|---|
| Announcement date: | Apr 04 2011 |
| Deal value, US$m: | n/d |
Details
| Announcement date: | Apr 04 2011 |
|---|---|
| Industry sectors: |
Bigpharma
Pharmaceutical |
| Therapy areas: |
Cardiovascular
»
Hypertension
|
| Technology types: |
Small molecules
|
| Deal components: |
Co-promotion
Promotion |
| Stages of development: |
Marketed
|
| Geographic focus: |
Asia
»
China
|
Financials
| Deal value, US$m: | n/d |
|---|
Termsheet
Pfizer has agreed to co-promote a hypertension drug from Daiichi Sankyo Pharma in China.
Press Release
Pfizer has agreed to co-promote a hypertension drug from Daiichi Sankyo Pharma in China. The two companies will cooperate on selling olmesartan medoxomil, known as Benicar in the US and Olmetec in the EU and Canada. It is a member of the angiotensin II receptor antagonist class of drugs.
Filing Data
Not available.
Contract
Not available.